CoChat
Sign Up
Cited by 119

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Learning by Failing: Ideas and Concepts to Tackle γ-Secretases in Alzheimer's Disease and Beyond

De Strooper, Bart, Chávez Gutiérrez, Lucía·2015·Annual Review of Pharmacology and Toxicology
DOI 10.1146/annurev-pharmtox-010814-124309
Open this paper in CoChat — free account

Abstract

γ-Secretases are a group of widely expressed, intramembrane-cleaving proteases involved in many physiological processes. Their clinical relevance comes from their involvement in Alzheimer's disease, cancer, and other disorders. A clinical trial with the wide-spectrum γ-secretase inhibitor semagacestat has, however, demonstrated that global inhibition of all γ-secretases causes serious toxicity. Evolving insights suggest that selective inhibition of one of these proteases, or more subtle modulation of γ-secretases by stimulating their carboxypeptidase-like activity but sparing their endopeptidase activity, are potentially highly interesting approaches. The rapidly growing knowledge of regulation, assembly, and specificity of these intriguing protein complexes and the potential advent of high-resolution structural information could dramatically change the perspective on safe and efficacious γ-secretase inhibition in various disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1146/annurev-pharmtox-010814-124309

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A possible cause of clinical failure of β- and γ-secretase inhibitor therapies is difficulty inhibiting these proteinases without side effects from non-targeted proteolytic inhibition on their many physiological substrates.

    “a possible cause of clinical failure could be the difficulty of inhibiting these proteinases without causing side effects resulting from non-targeted proteolytic inhibition on their many physiological substrates”

    From Emerging Alternative Proteinases in APP Metabolism and Alzheimer’s Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP (2019) · cites this paper as De Strooper and Chavez Gutierrez, 2015

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 128

  1. 10.1056/NEJMe1313943 · DOI · Paper page
  2. 10.1056/NEJMoa1210951 · DOI · Paper page
  3. 10.1038/emboj.2012.173 · DOI · Paper page
  4. 10.1074/jbc.M112.377465 · DOI · Paper page
  5. 10.1038/emboj.2013.146 · DOI · Paper page
  6. 10.1016/j.bbamem.2013.04.016 · DOI
  7. 10.1038/ng1095-219 · DOI · Paper page
  8. 10.1038/34910 · DOI · Paper page
  9. 10.1016/S0896-6273(03)00205-8 · DOI · Paper page
  10. 10.1038/19077 · DOI
  11. 10.1074/jbc.M405597200 · DOI
  12. 10.1038/ncb960 · DOI
  13. 10.1073/pnas.1037392100 · DOI
  14. 10.1016/j.jmb.2008.10.078 · DOI
  15. 10.1074/jbc.M705248200 · DOI
  16. 10.1523/JNEUROSCI.0954-13.2013 · DOI
  17. 10.1073/pnas.1735338100 · DOI
  18. 10.1038/nature08146 · DOI
  19. 10.1074/jbc.M604997200 · DOI
  20. 10.1523/JNEUROSCI.3614-06.2006 · DOI
  21. 10.1074/jbc.M802461200 · DOI
  22. 10.1523/JNEUROSCI.1163-08.2008 · DOI
  23. 10.1523/JNEUROSCI.3318-10.2010 · DOI
  24. 10.1038/nature11801 · DOI
  25. 10.1523/JNEUROSCI.2362-09.2009 · DOI · Paper page
  26. 10.1074/jbc.M211161200 · DOI
  27. 10.1523/JNEUROSCI.1575-04.2005 · DOI · Paper page
  28. 10.1074/jbc.M513453200 · DOI
  29. 10.1074/jbc.M707103200 · DOI
  30. 10.1074/jbc.M113.510131 · DOI
  31. 10.1038/emboj.2012.79 · DOI · Paper page
  32. 10.1523/JNEUROSCI.1443-10.2010 · DOI
  33. Barret AJ, 2013, Handbook of Proteolytic Enzymes
  34. 10.1110/ps.051475305 · DOI
  35. 10.1152/physiol.00009.2008 · DOI
  36. 10.1016/j.cell.2013.10.053 · DOI
  37. 10.1016/j.nbd.2004.08.002 · DOI
  38. 10.1074/jbc.M405768200 · DOI
  39. 10.1073/pnas.0408901102 · DOI
  40. 10.1523/JNEUROSCI.3814-04.2005 · DOI
  41. 10.1101/gad.13.21.2801 · DOI
  42. 10.1073/pnas.96.21.11872 · DOI
  43. 10.1073/pnas.0800507105 · DOI
  44. 10.1016/j.neuron.2004.12.054 · DOI
  45. 10.1126/science.1171176 · DOI
  46. 10.1124/jpet.105.100271 · DOI
  47. 10.1523/JNEUROSCI.1451-12.2012 · DOI
  48. 10.1016/j.bbamem.2013.06.005 · DOI
  49. 10.1038/35017062 · DOI
  50. 10.1038/35015085 · DOI · Paper page
  51. 10.1021/jm900188z · DOI
  52. 10.1046/j.1471-4159.2001.00012.x · DOI
  53. 10.1074/jbc.M513012200 · DOI
  54. 10.1073/pnas.0407640102 · DOI
  55. 10.1371/journal.pone.0050759 · DOI
  56. 10.1523/JNEUROSCI.4264-11.2012 · DOI · Paper page
  57. Hyde LA, 2013, Int. J. Alzheimer's Dis., 2013, 823528
  58. 10.1001/archneurol.2012.2194 · DOI
  59. 10.1124/jpet.112.199356 · DOI
  60. 10.1021/bi301137h · DOI
  61. 10.1021/jm301741t · DOI
  62. 10.1021/ja037131v · DOI
  63. 10.1021/jm049788c · DOI
  64. 10.1038/emboj.2011.372 · DOI
  65. 10.1038/nrd3288 · DOI
  66. 10.1124/jpet.106.114330 · DOI
  67. 10.1074/jbc.M708870200 · DOI
  68. 10.1021/bi200026m · DOI
  69. Acx H, 2013, J. Biol. Chem., 280, 4346
  70. 10.1038/nm1235 · DOI
  71. 10.1172/JCI200318162 · DOI
  72. 10.2174/13892037113149990144 · DOI
  73. 10.1021/bi400377p · DOI
  74. 10.1021/jm101168r · DOI
  75. 10.1186/1750-1326-7-61 · DOI · Paper page
  76. Gijsen HJM, 2012, Int. J. Alzheimer's Dis., 2012, 295207
  77. 10.1016/j.neuron.2010.08.018 · DOI
  78. 10.1021/bi401537v · DOI
  79. 10.1186/alzrt173 · DOI
  80. 10.1096/fj.05-5530fje · DOI
  81. 10.1038/nature07055 · DOI
  82. 10.1073/pnas.1003026107 · DOI
  83. 10.1074/jbc.M110.101287 · DOI
  84. 10.1021/cn200098p · DOI
  85. 10.1371/journal.pone.0030484 · DOI
  86. 10.1074/jbc.C111.276972 · DOI
  87. 10.1074/jbc.M112.398602 · DOI
  88. 10.1038/ncomms1129 · DOI
  89. 10.1016/S0896-6273(01)00512-8 · DOI
  90. 10.1074/jbc.M503570200 · DOI
  91. 10.1038/nature04667 · DOI
  92. 10.1073/pnas.0502768102 · DOI
  93. 10.1038/nature09325 · DOI
  94. 10.1083/jcb.200609180 · DOI
  95. 10.1186/1750-1326-2-4 · DOI
  96. 10.1074/jbc.M112.370924 · DOI
  97. 110. Olsson B, Legros L, Guilhot F, Strömberg K, Smith J, et al. 2014. Imatinib treatment and Aβ42 in humans.Alzheimer's Dement.10(Suppl.):S374–80 · DOI
  98. 10.1126/science.1223728 · DOI
  99. 10.1101/cshperspect.a004697 · DOI
  100. 10.1002/emmm.201200214 · DOI
  101. 10.1074/jbc.M801925200 · DOI
  102. 10.1021/bi300303g · DOI
  103. 10.1074/jbc.M112.356659 · DOI
  104. 10.1038/ncb1978 · DOI · Paper page
  105. 10.1007/s00018-011-0746-y · DOI
  106. 10.1074/jbc.M112.416503 · DOI · Paper page
  107. 10.1096/fj.09-133462 · DOI · Paper page
  108. 10.1073/pnas.1001647107 · DOI
  109. 10.1038/nm1485 · DOI
  110. 10.1038/cr.2010.3 · DOI
  111. 10.1126/science.1160649 · DOI
  112. 10.1038/cr.2012.167 · DOI
  113. 10.1038/nm.3023 · DOI
  114. 10.1371/journal.pone.0074680 · DOI
  115. 10.1073/pnas.0602321103 · DOI
  116. 10.1074/jbc.M110.193326 · DOI
  117. 10.1016/j.bbrc.2006.02.158 · DOI
  118. 10.1021/bi0494976 · DOI
  119. 10.1002/bit.24851 · DOI
  120. Cacquevel M, 2008, J. Neurochem., 104, 210, 10.1111/j.1471-4159.2007.05041.x · DOI
  121. 10.1021/bi300997e · DOI
  122. 10.1073/pnas.1202691109 · DOI
  123. 10.1074/jbc.M111.243063 · DOI
  124. 10.1093/hmg/11.9.1037 · DOI
  125. 10.1038/nature12822 · DOI
  126. 10.1038/nature12823 · DOI
  127. 10.1038/nature13567 · DOI
  128. 10.1074/jbc.M803040200 · DOI

Cited by

Sorted by citations

Metadata

Authors
De Strooper, B., & Chávez Gutiérrez, L.
Affiliations
VIB Center for the Biology of Disease, Vlaams Instituut voor Biotechnologie, BE-3000 Leuven, Belgium
Venue
Annual Review of Pharmacology and Toxicology
Publisher
Annual Reviews
Published
2015-01-06
Volume
55
Issue
1
Pages
419-437
ISSN
  • 0362-1642
  • 1545-4304
DOI
10.1146/annurev-pharmtox-010814-124309
Cited by
119
References
16
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review